Evidence map›Paper›PMID 41001447›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Complex Genetics and Regulatory Drivers of Hypermobile Ehlers-Danlos Syndrome: Insights from Genome-Wide Association Study Meta-analysis.

Taylor Petrucci-Nelson, Sacha Guilhaumou, Takiy E Berrandou, Cortney Gensemer, Adrien Georges, Matthew Huff, Margaux-Alison Fustier, Asraa Esmael, Josephine Henry, Olivia Jaye and 20 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Taylor Petrucci-NelsonDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Sacha GuilhaumouUniv Paris Cité, Inserm, PARCC, Paris, France.
Takiy E BerrandouUniv Paris Cité, Inserm, PARCC, Paris, France.ORCID 0000-0002-0525-3002
Cortney GensemerDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Adrien GeorgesUniv Paris Cité, Inserm, PARCC, Paris, France.
Matthew HuffDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Margaux-Alison FustierUniv Paris Cité, Inserm, PARCC, Paris, France.
Asraa EsmaelUniv Paris Cité, Inserm, PARCC, Paris, France.
Josephine HenryUniv Paris Cité, Inserm, PARCC, Paris, France.
Olivia JayeDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Ranan PhookanDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Sarah DooleyDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Kathryn ByerlyDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Brian LoizziDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Roman FennerDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Emma MachDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Amy WeintraubDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Victoria DaylorDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Julianna WeningerDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Natalie KorenDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Erika BistranDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Charlotte GriggsDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Molly GriggsDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Sydney SeveranceDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Rebecca ByrdDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.
Sunil PatelDepartment of Neurosurgery, Medical University of South Carolina, Charleston SC 29407, USA.
Steven A KautzDepartment of Health Sciences and Research, Medical University of South Carolina, Charleston, SC 29407, USA.
Anne MaitlandDivision of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, SC 29407, USA.
Nabila Bouatia-NajiUniv Paris Cité, Inserm, PARCC, Paris, France.ORCID 0000-0001-5424-2134
Russell A NorrisDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston SC 29407, USA.

Funding

Genetic and Molecular Mechanisms of hypermobile Ehlers Danlos SyndromeF32AI181339 · NIAID · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Cortney Anne Gensemer · 2024 to 2026
$170k
NIAID NIH HHS F32 AI181339
6 · The paper itself

Abstract

Background: Hypermobile Ehlers-Danlos syndrome (hEDS) is the most common subtype of EDS, a group of heritable connective tissue disorders. Clinically, hEDS is defined by generalized joint hypermobility and chronic musculoskeletal pain, but its impact extends beyond the musculoskeletal system. Affected individuals frequently experience autonomic, gastrointestinal, immune, and neuropsychiatric involvement, highlighting both the multisystemic nature of the condition and challenges of diagnosis. In contrast to other EDS subtypes with defined genetic causes, the molecular basis of hEDS has remained elusive. Methods: We conducted a genome-wide association study (GWAS) of hEDS across three case controls studies, including 1,815 cases and 5,008 ancestry-matched controls. Fixed-effects meta-analysis of 6.2 million variants was complemented with LDAK gene-based association testing, transcriptome-wide association studies, and integrative annotation across multiple tissues and cell types including eQTLs, enhancer marks and open chromatin accessibility profiles, supported by luciferase assays on one candidate variant. LD-score genetic correlations were assessed between hEDS and 19 frequently reported comorbid conditions. Results: Two loci reached genome-wide significance, including a regulatory region near the atypical chemokine receptor 3 gene ( Conclusions: These results establish the first evidence of common variant contributions to hEDS, supporting a complex, multisystem model involving neuroimmune-stromal dysregulation. Our findings add novel indications to hEDS pathogenesis and provide solid foundations for future molecular definition and therapeutic discovery.

Indexed as

Genome-wide association studyHypermobile Ehlers-Danlos Syndromeneurodevelopmentneuroimmune signaling

Identifiers

PMID41001447
PMCPMC12458961

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.